Best practices for intrathecal drug delivery for pain

Neuromodulation

Volumn 17, Issue 4, 2014, Pages 354-372

  Prager, Joshua ^a   Deer, Timothy ^b   Levy, Robert ^c   Bruel, Brian ^d   Buchser, Eric ^e   Caraway, David ^f   Cousins, Michael ^g   Jacobs, Marilyn ^h   McGlothlen, Gail ⁱ   Rauck, Richard ^j   Staats, Peter ^k   Stearns, Lisa ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Anesthesiology   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Anesthesiology Center for Neuromodulation   (Switzerland)

^f Anesthesiology Pain Relief Center St Mary's Regional Medical Center   (United States)

^g ROYAL NORTH SHORE HOSPITAL   (Australia)

^h Clinical Psychology   (United States)

ⁱ Napa Pain Institute   (United States)

^j Anesthesiology   (United States)

^k Anesthesiology Metzger Staats Pain Management   (United States)

^l Anesthesiology Valley Cancer Pain Treatment Center   (United States)

more..

Author keywords

Best practices; chronic pain; intrathecal catheter; intrathecal drug delivery; intrathecal pump; morphine; opioid; ziconotide

Indexed keywords

MORPHINE SULFATE; OMEGA CONOTOXIN MVIIA; PLACEBO; ANALGESIC AGENT;

ABNORMAL VISION; ANESTHESIST; ANOREXIA; ANXIETY DISORDER; APHASIA; ARTICLE; ASTHENIA; ATAXIA; AUSTRALIA; CATATONIA; CATHETER; CHRONIC PAIN; CLINICAL PSYCHOLOGY; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG SAFETY; DYSESTHESIA; EDEMA; EQUIPMENT FAILURE; EUROPE; FEVER; GAIT DISORDER; HALLUCINATION; HEADACHE; HUMAN; IMPLANTABLE PUMP; LETHARGY; MEDICAL DEVICE COMPLICATION; MEDICATION ERROR; MEMORY DISORDER; MUSCLE HYPERTONIA; NAUSEA; NAUSEA AND VOMITING; NEUROSURGEON; NYSTAGMUS; PAIN; PARANOID PSYCHOSIS; PARESTHESIA; PATIENT CONTROLLED ANALGESIA; PATIENT MONITORING; PATIENT SELECTION; PHYSICAL MEDICINE; PRACTICE GUIDELINE; PRURITUS; PSYCHOSIS; REGISTERED NURSE; RESPIRATION DEPRESSION; SEXUAL DYSFUNCTION; SOMNOLENCE; SPEECH DISORDER; SURGICAL INFECTION; UNITED STATES; URINE RETENTION; VERTIGO; VOMITING; WOUND HEALING; ANALGESIA; INTRASPINAL DRUG ADMINISTRATION; PAIN MEASUREMENT; PROCEDURES; STANDARDS;

ANALGESICS; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, SPINAL; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT;

EID: 84903543641     PISSN: 10947159     EISSN: 15251403     Source Type: Journal    
DOI: 10.1111/ner.12146     Document Type: Article

References (82)

1. Onofrio BM, Yaksh TL, Arnold PG,. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc 1981; 56: 516-520.
2. Medtronic marketing data. Minneapolis, MN: Medtronic Inc., 2013.
3. Cousins MJ, Mather LE,. Intrathecal and epidural administration of opioids. Anesthesiology 1984; 61: 276-310.
4. Krames ES, Olson K,. Clinical realities and economic considerations: patient selection in intrathecal therapy. J Pain Symptom Manage 1997; 14: S3-S13.
5. Joint Commission on Accreditation of Healthcare Organizations. Comprehensive Accreditation Manual for Ambulatory Care. 1999 -2000.
6. International Association for the Study of Pain. Declaration of Montreal. http://www.iasp-pain.org/Content/NavigationMenu/Advocacy/ DeclarationofMontr233al/default.htm. Accessed Dec. 9, 2013.
7. Deer T, Winkelmüller W, Erdine S, Bedder M, Burchiel K,. Intrathecal therapy for cancer and nonmalignant pain: patient selection and patient management. Neuromodulation 2002; 2: 55-66.
8. Deer T, Chapple I, Classen A, et al. Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain. Pain Med 2004; 5: 6-13.
9. Krames E,. Intrathecal infusional therapies for intractable pain: patient management guidelines. J Pain Symptom Manage 1993; 8: 451-453.
10. Medtronic 2011 product performance report. Minneapolis, MN: Medtronic Inc., 2011.
11. Coffey RJ, Owens ML, Broste SK, et al. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat non-cancer pain. Anesthesiology 2009; 111: 881-891.
12. Rathmell JP, Miller MJ,. Death after initiation of intrathecal drug therapy for chronic pain. Anesthesiology 2009; 111: 706-708.
13. Deer TR, Smith HS, Cousins M, et al. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. Pain Physician 2010; 13: E175-E213.
14. Deer TR,. A critical time for practice change in the pain treatment continuum: we need to reconsider the role of pumps in the patient care algorithm. Pain Med 2010; 11: 987-990.
15. Prager JP,. Minimizing the risks of intrathecal therapy. Lecture, Scientific Meeting of The North American Neuromodulation Society. 2009.
16. Hassenbusch S, Portenoy RK, Cousins M, et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-report of an expert panel. J Pain Symptom Manage 2004; 27: 540-563.
17. Ghafoor VL, Epshetyn M, Carlson GH, et al. Intrathecal drug therapy for long-term pain management. Am J Health-Syst Pharm 2007; 64: 2447-2461.
18. American Society of Anesthesiologists Task Force on Neuraxial Opioids, Horlocker TT, Burton AW, et al. Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration. Anesthesiology 2009; 110: 218-230.
19. Warner M, Chen LH, Makuc DM,. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. In NCHS data brief, no 22. Hyattsville, MD: National Center for Health Statistics, 2009; 1-7.
20. Coffey RJ, Owens ML, Broste SK, et al. Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain. Pain Med 2010; 11: 1001-1009.
21. Ballantyne JC, Mao J,. Opioid therapy for chronic pain. N Engl J Med 2003; 349: 1943-1953.
22. Sylvester RK, Lindsay SM, Schauer C,. The conversion challenge: from intrathecal to oral morphine. Am J Hosp Palliat Care 2004; 21: 143-147.
23. DuPen SL, DuPen A,. The dilemma of opioid conversion in intrathecal therapy. Sem Pain Med 2003; 1: 260-264.
24. Galer BS, Coyle N, Pasternak GW, Portenoy RK,. Individual variability in the response to different opioids: report of five cases. Pain 1992; 49: 87-91.
25. Deer T, Krames ES, Hassenbusch SJ, et al. Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2007; 10: 300-328.
26. Krames ES,. Intraspinal opioid therapy for chronic nonmalignant pain: current practice and clinical guidelines. J Pain Symptom Manage 1996; 11: 333-352.
27. Infumorph 200, Infumorph 500 [package insert]. Eatontown, NJ: West-Ward Pharmaceuticals; 2011.
28. Raffaeli W, Marconi G, Fanelli G, et al. Opioid-related side-effects after intrathecal morphine: a prospective, randomized, double-blind dose-response study. Eur J Anesthes 2006; 23: 605-610.
29. Stearns L, Boortz-Marx R, DuPen S, et al. Intrathecal drug delivery for management of cancer pain. A multidisciplinary consensus of best clinical practices. J Supportive Oncol 2005; 3: 399-408.
30. Wallace MS, Rauck R, Fisher R, et al. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg 2008; 106: 628-637.
31. Ilias W, Le Polain B, Buchser E, Demartini L, oPTiMa Study Group. Patient-controlled analgesia in chronic pain patients: experience with a new device designed to be used with implanted programmable pumps. Pain Pract 2008; 8: 164-170.
32. Chaney MA,. Side effects of intrathecal and epidural opioids. Can J Anaesth 1995; 42: 891-903.
33. Anderson VC, Burchiel KJ,. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999; 44: 289-300.
34. Winkelmuller M, Winkelmuller W,. Long-term effects of continuous intrathecal opioid treatment in chronic pain of non-malignant etiology. J Neurosurg 1996; 85: 458-467.
35. Bailey PL, Rhondeau S, Schafer PG, et al. Dose-response pharmacology of intrathecal morphine in human volunteers. Anesthesiology 1993; 79: 49-59.
36. Anderson VC, Cooke B, Burchiel KJ,. Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study. Pain Med 2001; 2: 287-297.
37. Aldrete JA, Couto da Silva JM,. Leg edema from intrathecal opiate infusions. Eur J Pain 2000; 4: 361-365.
38. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000; 85: 2215-2222.
39. Ummenhofer WC, Arends RH, Shen DD, Bernards CC,. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology 2000; 92: 739-753.
40. Ruan X,. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician 2007; 10: 357-365.
41. Smith HS, Deer TR,. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Therap Clin Risk Manage 2009; 5: 521-534.
42. Ziconotide [package insert]. NDA 21-060: labeling supplement Prialt® (ziconotide intrathecal infusion). Cambridge, MA: Elan Pharmaceuticals, Inc, 2004.
43. Fisher R, Hassenbusch S, Krames ET, et al. A consensus statement regarding the present suggested titration for Prialt (ziconotide). Neuromodulation 2005; 8: 151-154.
44. Wallace MS, Charapata SG, Fisher R, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 2006; 9: 75-86.
45. Rauck R, Wallace MS, Leong MS, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006; 31: 393-406.
46. Follett KA, Boortz-Marx RL, Drake JM, et al. Prevention and management of intrathecal drug delivery and spinal cord stimulation system infections. Anesthesiology 2004; 100: 1582-1594.
47. Mangram AJ, Horan TC, Pearson MI, et al. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999; 20: 217-273.
48. Darouiche RO, Wall MJ, Itani KMF, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010; 362: 18-26.
49. McHugh SM, Collins CJ, Corrigan MA, et al. The role of topical antibiotics used as prophylaxis in surgical site infection prevention. J Antimicrob Chemother 2011; 66: 693-701.
50. Wilkins RG, Unverdorben M,. Wound cleaning and wound healing: a concise review. Adv Skin Wound Care 2013; 26: 160-163.
51. Pfeiffer PK, Jorgensen S, Kristiansen TB, et al. Protective effect of topical antibiotics in breast augmentation. Plast Reconstr Surg 2009; 124: 629-634.
52. Follett KA, Burchiel K, Deer T, et al. Prevention of intrathecal drug delivery catheter-related complications. Neuromodulation 2003; 6: 32-41.
53. Clinical Reference Guide. 2013. http://professional.medtronic.com/wcm/ groups/mdtcom-sg/@mdt/@neuro/documents/documents/synchii-ref-guide.pdf Accessed April 20, 2013.
54. Turner JA, Sears JM, Loeser JD,. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin J Pain 2007; 23: 180-195.
55. Jones RL, Rawlins PK,. The diagnosis of intrathecal infusion pump system failure. Pain Physician 2005; 8: 291-296.
56. SynchroMed® EL & SynchroMed II. Pump corrosion from nonindicated drug formulations resulting in permanent pump stalls. Minneapolis, MN: Medtronic Inc., 2010.
57. Use of unapproved drugs with the Synchromed® implantable infusion pump. Minneapolis, MN: Medtronic Inc., 2012.
58. Bernards CM,. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 2006; 105: 169-178.
59. Flack SH, et al. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg 2011; 112: 460-464.
60. Laterra J, Keep R, Lorris-Betz A, et al. Blood-brain-cerebrospinal fluid barriers. In:, Siegel GI, Agranoff BW, Albers RW, et al, eds. Basic neurochemistry-molecular, cellular and medical aspects, 6th ed. Philadelphia: Lippincott-Raven, 1999: 672-689.
61. Important clinical information about pocket fills. Minneapolis, MN: Medtronic Inc., 2011.
62. Gofeld M, McQueen CK,. Ultrasound-guided intrathecal pump access and prevention of the pocket fill. Pain Med 2011; 12: 607-611.
63. Taha J, Favre J, Janszen M, et al. Correlation between withdrawal symptoms and medication pump residual volume in patients with implantable SynchroMed pumps. Neurosurgery 2004; 55: 390-394.
64. Albright AL, Turner M, Pattisapu JV,. Best-practice surgical techniques for intrathecal baclofen therapy. J Neurosurg 2006; 104: 233-239.
65. North RB, Cutchis PN, Epstein JA, Long DM,. Spinal cord compression complicating subarachnoid infusion of morphine: case report and laboratory experience. Neurosurgery 1991; 29: 778-784.
66. Updated information-inflammatory mass (granuloma) at or near the distal tip of intrathecal catheters. Minneapolis, MN: Medtronic Inc., 2008.
67. Deer T, et al. Polyanalgesic consensus conference-2012 consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation 2012; 15: 483-496.
68. Yaksh TL, Hassenbusch S, Burchiel K, et al. Inflammatory masses associated with intrathecal drug infusion, a review of preclinical evidence and human data. Pain Med 2002; 3: 300-312.
69. Coffey RJ, Burchiel K,. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations in 41 patients. Neurosurgery 2002; 50: 78-87.
70. Deer T, Krames ES, Hassenbusch S, et al. Management of intrathecal catheter-tip inflammatory masses: an updated 2007 consensus statement from an expert panel. Neuromodulation 2008; 11: 77-91.
71. MRI guidelines. Minneapolis, MN: Medtronic Inc., 2010.
72. Naumann C, Erdine S, Koulousakis A, et al. Drug adverse events and system complications of intrathecal opioid delivery for pain: origins, detection, manifestations, and management. Neuromodulation 1999; 2: 92-107.
73. Prager JS, Jacobs M,. Evaluation of patients for implantable pain modalities: medical and behavioral assessment. Clin J Pain 2001; 17: 206-214.
74. Melzack R, Casey KL,. Sensory, motivational and central determinants of chronic pain: a new conceptual model. In:, Kenshalo DR, ed. The skin senses. Springfield, IL: Thomas, 1968: 432.
75. Young-Casey C, Greenberg MA, Nicassio PM, et al. Transition from acute to chronic pain and disability: a model including cognitive, affective, and trauma factors. Pain 2008; 134: 69-79. Epub 2007 May.
76. Benjamin S, Morris S, McBeth J, et al. The association between chronic widespread pain and mental disorder: a population-based study. Arthritis Rheum 2000; 43: 561-567.
77. Eccleston CW, Williams AC, Morley S,. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2011;(2). DOI: 10.1002/14651858.CD007407.pub2.
78. Roy R,. Psychosocial interventions for chronic pain: in search of evidence. New York: Springer, 2008.
79. Molloy AR, Nicholas MK, Asghari A, et al. Does a combination of intensive cognitive-behavioral pain management and a spinal implantable device confer any advantage? A preliminary examination. Pain Pract 2006; 6: 96-103.
80. Flor H, Turk DC,. Chronic pain: an integrated biobehavioral approach. Seattle: IASP Press, 2011.
81. Ivey SL, Scheffler R, Zassali J,. Supply dynamics of the mental health workforce: implications for health policy. Milbank Q 1998; 76: 25-58.
82. Burton AW, Deer T, Wallace MS, Rauck RL, Grigsby E,. Considerations and methodology for trialing ziconotide. Pain Physician 2010; 13: 23-33.